Edison's note out this morning on Research Tree: "In H116 MedicX Fund continued to selectively add assets, despite a highly competitive UK investment market, and it maintains a strong investment pipeline in both the UK and Republic of Ireland. Profit progression during the period was limited by the time between drawing on funding and income generation from investment; as this unwinds, earnings growth should pick up, supported by the new management fee structure. As a long-term investor in modern primary care properties in the UK and the Republic of Ireland, the fund should..."
"Intercede has reported prelims in line with the April trading update, detailing revenue growth of 25% to £11.0m. Forecasts continue to assume 30% growth into FY17 and FY18 in line with the board's strategic ambitions to 2020, and a target of EBITDA and cash flow breakeven as profit is reinvested in further R&D. With new products MyTAM and RapID generating less than 5% of revenue and material growth all therefore currently derived from the existing profitable MyID product set, we look forward to growth and newsflow in..." finnCap note out this morning on Research Tree
finnCap published a note this morning: "Proactis has announced a contract win with P&O FerryMasters, extending the existing relationship a further five years and implementing the Supplier Network. The new platform will streamline electronic communication across the supply chain, and incorporates the potential of the Accelerated Payment Facility to the supplier base of 7,850, with a total spend environment of c£350m. While the uplift to our forecasts is minimal, the significance is material, again demonstrating the extension of an existing relationship and the..." taken from Research Tree
Northland also published a note this morning: "ValiRx continues to progress its two lead programmes. VAL201’s Phase 1/2 trial is moving into its expansion phase with the inclusion of additional clinical trial centres. To date, no drug related significant adverse events have been reported. VAL401 is close to commencing its clinical programme. The trial will take place in Georgia, with sites, investigators and facilities now confirmed."
Northland capital note out this morning: "Stratex International has increased the unsecured short-term loan to Goldstone Resource, a company that Stratex has a 33.45% interest in, from US$100,000 to US$350,000. All other terms remain the same. The loan will be used for working capital and to satisfy the amicable settlement between Goldstone and its former CEO Jurie Wessels... It is positive for both Stratex International and Goldstone Resources (33.45%-owned by Stratex) that an amicable settlement between Goldstone and its former CEO Jurie Wessels has been reached." Scraped from Research tree
Northland also published a note..."ImmuPharma issued an update on the progress of its Phase 3 clinical trial of LupuzorTM, its lead programme for the potential treatment of Lupus. The company confirmed that the first European sites have now commenced dosing Lupus patients. Recruitment in the study will occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe. ImmuPharma’s lead programme is progressing to plan, with patients now being dosed in Europe and America. The Phase 3 clinical trial is expected to deliver a read-out by the end of 2017." pulled from Research Tree
Panmure Gordon note out this morning on Research Tree: "Following today’s announcements we place our recommendation and earnings forecasts under review. Central Rand Gold has entered into a binding Joint Venture Tolling Agreement with a third party supplier of ore for the sourcing and processing of gold- bearing material through the metallurgical plant at Central Rand Gold. The Tolling Venture envisages the processing through the Company’s metallurgical plant of a minimum of 18,000 tonnes per month, commencing from July 2016."
Panmure published a note this morning on Research Tree: "This morning ImmuPharma has announced the commencement of dosing in the first European patients in the company’s pivotal Phase III clinical study for Lupuzor™. This means that both US and European sites are now dosing patients in the Phase III trial (recruitment is expected in up to 45 investigator sites) and with Lupus continuing to represent a major unmet medical need we consider the ongoing demand for an effective treatment – highlighted by still torpid sales of GSK’s Benlysta – represents a major opportunity for ImmuPhara."
Panmure note out this morning on Researchtree: "Johnny Cash reminds us that SUSE is in a competitive niche – but it is good with its knuckles. A brace of trade news from SUSE reminds us that it plays at the heart of a global Linux open source market. To reiterate our investment view: Micro Focus is likely to ‘do something’ with SUSE over time – either a trade sale, a US listing or a de-merge in London. However, it is unlikely this year as the new executive team are finding their feet. The closest valuation peer, Linux and Hortonworks, may suggest that SUSE might sit more..."
Edison published a note this morning on Research Tree: "Gaming Realms has announced a strategic partnership with the Ayima digital marketing agency whereby it is injecting its QuickThink Media (QTM) assets in return for a 10% stake valued at £540k. The rationale for the deal is to allow Gaming Realms’ management to further focus on its core strength, being the development and publishing of mobile optimised social and real money games, while also strengthening QTM’s outlook by placing it within a growing complementary business."